Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 7;11:24. doi: 10.1038/s41467-019-13808-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a Paclitaxel (PTX) treatment increases the prevalence of subG1, G2/M, and >4N populations in RepID-deficient HCT116 cells. HCT116 RepID WT and KO cells treated with PTX for 24 h were labeled with EdU for 30 min prior to collection and analyzed by FACS. Percentage of each cell cycle phase was indicated in EdU-positive histogram plots (insets). b Bar graph depicting the cell cycle distribution of cells collected in a from three biologically independent experiments (left panel). Immunoblot analysis showing elevated accumulation of phosphorylated histone H3 in RepID-deficient cells in response to PTX treatment as in a (right panel). c Colony-formation assay with HCT116 RepID WT and KO cells upon PTX treatment. Bar charts indicate colony number, and the percentage of covered area is provided above the bars. d Nocodazole sensitivity is not changed by RepID deficiency. e–h Failure of RepID-CRL4^RBBP7-based BUB3 degradation leads to increased sensitivity to PTX treatment. e Depleted/overexpressed HCT116 cells as indicated were treated with PTX and analyzed by FACS. Histogram indicates asynchronized (upper panel) or PTX-treated cells (bottom panel). f Percentage of cells in subG1, G1, G2/M, and >4N phase in e. g Nuclear staining after PTX treatment in depleted/overexpressed HCT116 cells as indicated. Red arrows indicate multinucleated cells. Scale bar: 10 μm. h Percentage of multinucleated cells and micronuclei in g. Error bars in all results represent standard deviation from three independent experiments (*p value < 0.05, **p < 0.01, ***p < 0.001, n.s. not significant, Student’s t test).